1 January – 30 June (unaudited)
|
kEUR |
H1 2024 |
H1 2023 |
|
|
|
|
|
|
|
Revenue |
135,043 |
131,834 |
|
|
Other operating income |
|
787 |
1,544 |
|
Total income |
|
135,830 |
133,378 |
|
|
|
|
|
|
Cost of sales |
-125,287 |
-144,006 |
|
|
Gross profit / (loss) |
|
10,543 |
-10,628 |
|
|
|
|
|
|
Marketing and sales expenses |
|
-1,922 |
-1,993 |
|
Research expenses |
|
-451 |
-746 |
|
General and administrative expenses |
-20,741 |
-21,097 |
|
|
Total operating expenses |
|
-23,114 |
-23,836 |
|
|
|
|
|
|
Operating result (EBIT) |
|
-12,571 |
-34,464 |
|
|
|
|
|
|
Financial income |
|
8,873 |
21 |
|
Financial expenses |
|
-8,613 |
-4,784 |
|
Total financial result |
|
260 |
-4,763 |
|
|
|
|
|
|
Result before income taxes |
|
-12,311 |
-39,227 |
|
|
|
|
|
|
Income tax |
|
925 |
4,961 |
|
Result for the period |
|
-11,386 |
-34,266 |
|
|
|
|
|
|
Attributable to shareholders of PolyPeptide Group AG |
|
-11,386 |
-34,266 |
|
|
|
|
|
|
Earnings per share in EUR, basic |
|
-0.35 |
-1.04 |
|
Earnings per share in EUR, diluted |
|
-0.35 |
-1.04 |